Alkermes plc
31.45+0.45 (+1.45%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · ALKS · USD
Key Stats
Market Cap
5.19BP/E (TTM)
15.65Basic EPS (TTM)
2.01Dividend Yield
0%Recent Filings
8-K
Alkermes plc announces agreement to acquire Avadel Pharmaceuticals plc, adding LUMRYZ to its portfolio and accelerating entry into the sleep medicine market.
Alkermes plc has entered into a definitive agreement to acquire Avadel Pharmaceuticals plc for $18.50 per share in cash plus a contingent value right (CVR) for an additional $1.50 per share, valuing Avadel at up to $2.1 billion. The acquisition, approved by both boards, is expected to close in Q1 2026 and aims to enhance Alkermes' revenue growth and profitability by integrating Avadel's commercial product LUMRYZ for narcolepsy treatment.
8-K
Alkermes names new CFO
Alkermes plc appointed Joshua Reed as Senior Vice President and Chief Financial Officer, effective September 15, 2025, succeeding interim CFO Blair C. Jackson. Reed, with over 30 years in biotech finance from roles at Omega Therapeutics, Aldeyra Therapeutics, and Bristol Myers Squibb, brings strategic expertise to bolster the company's financial foundation. His package includes a $615,000 base salary, 50% target bonus, and $3.5 million equity grant vesting over four years. This move sharpens Alkermes' focus on innovation and growth amid pipeline advances.
8-K
VIVITROL generic deal, LYBALVI suits
Alkermes inked an authorized generic supply deal for VIVITROL with Amneal on September 9, 2025, allowing U.S. distribution starting from a third-party generic launch around January 2027, capped at 15% of 2024 unit sales. APIL supplies at a premium to manufacturing costs, sharing net profits with Amneal for one year. Meanwhile, Alkermes sued Teva, Apotex, and MSN in August 2025 over LYBALVI patent infringements from ANDA filings, triggering 30-month FDA approval stays. These moves defend key revenue streams amid generic threats.
8-K
Strong alixorexton phase 2 data
Alkermes unveiled robust phase 2 Vibrance-1 results on September 8, 2025, showing once-daily alixorexton (4-8 mg) significantly boosted wakefulness in narcolepsy type 1 patients, with mean sleep latency hitting 24-28 minutes on the MWT versus placebo's decline, while slashing sleepiness scores to normal on the ESS and cutting cataplexy rates—statistically at 6 mg. The drug normalized fatigue and cognition too, yet sparked mild urinary and vision side effects that mostly faded fast. No serious adverse events emerged. Alkermes eyes phase 3 launch in Q1 2026, but future trials may falter on safety or efficacy.
8-K
Alkermes Q2 revenues dip slightly
Alkermes reported Q2 2025 revenues of $390.7 million, down slightly from $399.1 million last year due to expired INVEGA SUSTENNA royalties, yet proprietary products drove $307.2 million in sales, up 14% with VIVITROL at $121.7 million, ARISTADA $101.3 million, and LYBALVI $84.3 million. GAAP net income hit $87.1 million, bolstered by gross-to-net favorability. Cash swelled to $1.05 billion. The company holds 2025 guidance steady.
IPO
Website
Employees
Sector
Industry
ALVO
Alvotech
7.90+0.03
ALZN
Alzamend Neuro, Inc.
2.45+0.09
AMRX
Amneal Pharmaceuticals, Inc.
10.43+0.14
AVDL
Avadel Pharmaceuticals plc
18.90+0.31
BIIB
Biogen Inc.
147.86-1.27
GSK
GSK plc
45.93+2.23
NBIX
Neurocrine Biosciences, Inc.
138.02-9.36
NVS
Novartis AG
121.80-1.63
TAK
Takeda Pharmaceutical Company L
13.77-0.33
TEVA
Teva Pharmaceutical Industries
20.23+0.45